Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Saved in:
| Title: | Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). |
|---|---|
| Authors: | Bissonnette, R.1 rbissonnette@innovaderm.ca, Luger, T.2, Thaçi, D.3, Toth, D.4, Lacombe, A.5, Xia, S.6, Mazur, R.5, Patekar, M.5, Charef, P.5, Milutinovic, M.5, Leonardi, C.7, Mrowietz, U.8 |
| Source: | Journal of the European Academy of Dermatology & Venereology. Sep2018, Vol. 32 Issue 9, p1507-1514. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
